Table 3

Baseline characteristics of HCV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008

Total N=1175

HCV chronically infected patients N=1048

Sustained HCV responders N=127


Years since HCV diagnosis, median (IQR)

-

10 (6-14)

-

HCV genotype, N (%)

-

-

1

577 (56.0)

2

39 (3.8)

3

187 (18.1)

4

225 (21.8)

5 or other

3 (0.3)

HCV plasma RNA (Log10) (IU/ML), median (IQR)

-

6.2 (5.7-6.5)

-

Past anti HCV therapy, N (%)

Interferon alone

40 (3.4)

33 (3.1)

7 (5.5)

Interferon+ ribavirin

93 (7.9)

65 (6.2)

28 (22)

Pegylated interferon plus ribavirin

365 (31.1)

273 (26.0)

92 (72.5)

Cirrhosis*, N (%)

255 (25.2)

229 (25.0)

26 (26.8)

Documented decompensated liver disease, N (%)

32 (2.7)

27 (2.6)

5 (3.9)


* according to the study algorithm of cirrhosis (see Figure1)

Loko et al. BMC Infectious Diseases 2010 10:303   doi:10.1186/1471-2334-10-303

Open Data